Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea

Trial Profile

Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Exenatide (Primary) ; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Amylin Pharmaceuticals; AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Sep 2014 Results of a pooled analysis of trials NCT00641056, NCT01003184, and NCT00935532 were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 12 Jul 2014 This trial has been completed in Ireland and recruiting in United Kingdom as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top